Latest Conference Articles

Mast spoke with Dermatology Times about her conference workshop, what she's looking forward to ahead of this week's SDPA conference, and the importance of always maintaining a passion for patients.

When sessions, late-breaking research, and more conclude at SDPA Fall 2023, there is no shortage of things to do in Nashville.

Click here to answer today's poll.

The conference aimed at providing dermatology physician assistants with the latest in the field begins tomorrow in Nashville, Tennessee.

If you weren’t able to attend the 2023 Fall Clinical Dermatology Conference or want to review our latest coverage and interviews, our full recap has you covered.

Catch up on coverage from the final day of the 2023 Fall Clinical Dermatology Conference.

This study aimed to evaluate the association between the disease burden of psoriasis and the switching of systemic biologic therapies in patients with both psoriasis and psoriatic arthritis.

There is a lot of conversation drumming around the boxed warnings for newer JAK inhibitors, and fact versus fiction was discussed at Fall Clinical.

Susan Taylor, MD, walked Fall Clinical attendees through an in-depth hyperpigmentation session that included melasma and its mimickers.

Sandra Lee, MD, and other top acne experts took the stage to debate cases and treatments.

Primary and secondary melanoma prevention factors are necessary to reduce patients’ melanoma risk.

The latest CDC data shows an uptick in syphilis, which can lead to a rare form of alopecia or a presentation of psoriasis.

Catch up on coverage from the third day of the 2023 Fall Clinical Dermatology Conference.

Although still in its early stages, the program showcases the potential value of tangible interactions between dedicated navigators and patients in enhancing support and continuity of care.

Christopher Bunick, MD, PhD, reviews Cabtreo’s recent FDA approval and what the new triple-combination gel means for acne patients.

The pharmacokinetic profile of APG777, characterized by an extended half-life, increased exposure, and reduced clearance compared to lebrikizumab, is promising for patients with IL-13-driven diseases.

The goal of Arron et al’s study was to determine if the 40-GEP test could identify high-risk cSCC patients who would benefit from ART in controlling metastatic disease progression.

The positive outcomes observed in these cases underscore the potential for these products to revolutionize the way dermatology clinicians address visible signs of facial aging.

Shah is presenting alongside a panel of leading experts at Fall Clinical 2023.

Dawn Merritt, DO, and Mark Lebwohl, MD, took the stage to explain the history of CSU, the prevalence of testing and food avoidance, approved treatments, and monitoring treatment improvement for the condition.

Catch up on coverage from the second day of the 2023 Fall Clinical Dermatology Conference.

Francesca Tenconi, president and CEO of Children’s Skin Disease Foundation and Camp Wonder, presented at Fall Clinical 2023 about the challenges of chronic skin conditions in children.

If you weren’t able to attend the 2023 Inflammatory Disease Summit or want to review our latest coverage and interviews, our full recap has you covered.

Kristine Kucera, PA-C, gave an in-depth overview of the JAK-STAT pathway at the 2023 Inflammatory Disease Summit.

April Armstrong, MD, MPH, and Peter Lio, MD, explained the science behind how AD impacts quality of life and biologics on the market to enhance treatment plans.

Hasbargen presented clinical cases alongside James Del Rosso, DO, at IDS 2023.

Kwatra reviewed skin lesions in PN and important treatment considerations for patients at Fall Clinical.

Catch up on coverage from the first day of the 2023 Fall Clinical Dermatology Conference and the Inflammatory Disease Summit.